Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2008; 51:708-715, doi:10.1016/j.jacc.2007.10.035
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View CVN News Brief
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (19)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kirtane, A. J.
Right arrow Articles by Stone, G. W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kirtane, A. J.
Right arrow Articles by Stone, G. W.

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

Paclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus

Pooled Analysis From 5 Randomized Trials

Ajay J. Kirtane, MD, SM*,1, Stephen G. Ellis, MD{dagger},1, Keith D. Dawkins, MD{ddagger},2, Antonio Colombo, MD§, Eberhard Grube, MD||, Jeffrey J. Popma, MD,3, Martin Fahy, MSc*, Martin B. Leon, MD*,4, Jeffrey W. Moses, MD*,5, Roxana Mehran, MD*,6 and Gregg W. Stone, MD*,7,*

* Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
{dagger} Cleveland Clinic, Cleveland, Ohio
{ddagger} Southampton University Hospital, Southampton, United Kingdom
§ San Raffaele Hospital, Milan, Italy
|| Helios Heart Center Siegburg, Siegburg, Germany
Caritas St. Elizabeth’s Medical Center, Boston, Massachusetts.

Manuscript received August 22, 2007; revised manuscript received October 5, 2007, accepted October 8, 2007.

* Reprint requests and correspondence: Dr. Gregg W. Stone, Columbia University Medical Center, The Cardiovascular Research Foundation, 111 East 59th Street, 11th Floor, New York, New York 10022. (Email: gs2184{at}columbia.edu).

Objectives: We sought to examine the safety and efficacy of paclitaxel-eluting stents (PES) in patients with diabetes mellitus (DM).

Background: Compared with patients without DM, patients with DM undergoing percutaneous coronary intervention are at increased risk for mortality and restenosis. The safety of drug-eluting stents in diabetic patients has recently been called into question by a published meta-analysis of randomized trials.

Methods: Patient-level data were pooled from 5 prospective, double-blind, randomized trials of PES versus bare-metal stents (BMS) (n = 3,513). Safety and efficacy outcomes through 4 years of follow-up were assessed among the 827 randomized patients (23.6%) with DM.

Results: Patients treated with PES and BMS has similar baseline characteristics among both the diabetic and nondiabetic cohorts within these trials. At 4-year follow-up, there were no significant differences between PES and BMS among diabetic patients in the rates of death (8.4% vs. 10.3%, respectively, p = 0.61), myocardial infarction (6.9% vs. 8.9%, p = 0.17), or stent thrombosis (1.4% vs. 1.2%, p = 0.92). Treatment of diabetic patients with PES compared with treatment with BMS was associated with a significant and durable reduction in target lesion revascularization over the 4-year follow-up period (12.4% vs. 24.7%, p < 0.0001). The relative safety and efficacy of PES compared with the relative safety and efficacy of BMS in diabetic patients extended to both those requiring and not requiring insulin.

Conclusions: In these 5 randomized trials in which patients with single, primarily noncomplex lesions were enrolled, treatment with PES compared with treatment with BMS was safe and effective, resulting in markedly lower rates of target lesion revascularization at 4 years, with similar rates of death, myocardial infarction, and stent thrombosis.

Abbreviations and Acronyms
  ARC = Academic Research Consortium
  BMS = bare-metal stent(s)
  CI = confidence interval
  DES = drug-eluting stent(s)
  DM = diabetes mellitus
  HR = hazard ratio
  IDDM = insulin-dependent diabetes mellitus
  MI = myocardial infarction
  NIDDM = noninsulin-dependent diabetes mellitus
  PES = paclitaxel-eluting stent(s)
  RVD = reference vessel diameter
  SES = sirolimus-eluting stent(s)
  TLR = target lesion revascularization
  TVR = target vessel revascularization




This article has been cited by other articles:


Home page
DiabetesHome page
T. Miki, T. Miura, H. Hotta, M. Tanno, T. Yano, T. Sato, Y. Terashima, A. Takada, S. Ishikawa, and K. Shimamoto
Endoplasmic Reticulum Stress in Diabetic Hearts Abolishes Erythropoietin-Induced Myocardial Protection by Impairment of Phospho-Glycogen Synthase Kinase-3{beta}-Mediated Suppression of Mitochondrial Permeability Transition
Diabetes, December 1, 2009; 58(12): 2863 - 2872.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
U. Stenestrand, S. K. James, J. Lindback, O. Frobert, J. Carlsson, F. Schersten, T. Nilsson, B. Lagerqvist, and for the SCAAR/SWEDEHEART study group
Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term of follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
Eur. Heart J., November 10, 2009; (2009) ehp424v1.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
A. J. Kirtane, R. Patel, C. O'Shaughnessy, P. Overlie, B. McLaurin, S. Solomon, L. Mauri, P. Fitzgerald, J. J. Popma, D. E. Kandzari, et al.
Clinical and Angiographic Outcomes in Diabetics From the ENDEAVOR IV Trial: Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease
J. Am. Coll. Cardiol. Intv., October 1, 2009; 2(10): 967 - 976.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
O. Frobert, B. Lagerqvist, J. Carlsson, J. Lindback, U. Stenestrand, and S. K. James
Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry).
J. Am. Coll. Cardiol., May 5, 2009; 53(18): 1660 - 1667.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. S. Brar, M. B. Leon, G. W. Stone, R. Mehran, J. W. Moses, S. K. Brar, and G. Dangas
Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis.
J. Am. Coll. Cardiol., May 5, 2009; 53(18): 1677 - 1689.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
E. Mahmud, J. A. Ormiston, M. A. Turco, J. J. Popma, N. J. Weissman, C. D. O'Shaughnessy, T. Mann, J. J. Hall, T. F. McGarry, L. A. Cannon, et al.
TAXUS Liberte Attenuates the Risk of Restenosis in Patients With Medically Treated Diabetes Mellitus: Results From the TAXUS ATLAS Program
J. Am. Coll. Cardiol. Intv., March 1, 2009; 2(3): 240 - 252.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. S. Brar, A. Y.-J. Shen, V. Aharonian, P. Mansukhani, and J. Kim
Reply.
J. Am. Coll. Cardiol., December 16, 2008; 52(25): 2213 - 2213.
[Full Text] [PDF]


Home page
BMJHome page
P. Agostoni and F. V. d. Branden
Drug eluting stents in patients with diabetes
BMJ, August 29, 2008; 337(aug29_3): a1359 - a1359.
[Full Text]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement